LAG3 Antikörper (N-Term) (FITC)
Kurzübersicht für LAG3 Antikörper (N-Term) (FITC) (ABIN1169106)
Target
Alle LAG3 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- Recognizes human LAG-3.
-
Kreuzreaktivität
- Human
-
Reinheit
- >95 % (SDS-PAGE)
-
Immunogen
- Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- Lot specific
-
Buffer
- In PBS containing 0.02 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
-
Short Term Storage: +4°C
Long Term Storage: +4°C
Keep conjugated formats at +4°C. Stable for at least 1 year after receipt when stored at +4°C. -
Haltbarkeit
- 12 months
-
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Andere Bezeichnung
- LAG-3
-
Hintergrund
- Lymphocyte activation gene 3 (LAG-3, CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.
-
UniProt
- P18627
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-